HEARTSCIENCES INC (HSCS)

US42254E3027 - Common Stock

3.3378  +0.08 (+2.31%)

Fundamental Rating

2

HSCS gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 191 industry peers in the Health Care Equipment & Supplies industry. HSCS has a bad profitability rating. Also its financial health evaluation is rather negative. HSCS is valied quite expensively at the moment, while it does show a decent growth rate.



Quickly go to:

1

1. Profitability

1.1 Basic Checks

HSCS had negative earnings in the past year.
In the past year HSCS has reported a negative cash flow from operations.
HSCS had negative earnings in each of the past 5 years.
In the past 5 years HSCS always reported negative operating cash flow.

1.2 Ratios

HSCS's Return On Assets of -84.93% is on the low side compared to the rest of the industry. HSCS is outperformed by 79.89% of its industry peers.
The Return On Equity of HSCS (-164.44%) is worse than 72.49% of its industry peers.
Industry RankSector Rank
ROA -84.93%
ROE -164.44%
ROIC N/A
ROA(3y)-164.63%
ROA(5y)-163.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Looking at the Gross Margin, with a value of 67.31%, HSCS is in the better half of the industry, outperforming 73.55% of the companies in the same industry.
In the last couple of years the Gross Margin of HSCS has grown nicely.
The Profit Margin and Operating Margin are not available for HSCS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 67.31%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.97%
GM growth 5YN/A

More info and screens

3

2. Health

2.1 Basic Checks

HSCS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for HSCS has been reduced compared to 1 year ago.
HSCS has a better debt/assets ratio than last year.

2.2 Solvency

HSCS has an Altman-Z score of -14.67. This is a bad value and indicates that HSCS is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -14.67, HSCS is doing worse than 84.66% of the companies in the same industry.
A Debt/Equity ratio of 0.01 indicates that HSCS is not too dependend on debt financing.
HSCS has a Debt to Equity ratio of 0.01. This is in the better half of the industry: HSCS outperforms 66.67% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z -14.67
ROIC/WACCN/A
WACC8.76%

2.3 Liquidity

A Current Ratio of 1.72 indicates that HSCS should not have too much problems paying its short term obligations.
With a Current ratio value of 1.72, HSCS is not doing good in the industry: 71.43% of the companies in the same industry are doing better.
HSCS has a Quick Ratio of 1.52. This is a normal value and indicates that HSCS is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.52, HSCS is not doing good in the industry: 60.32% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.72
Quick Ratio 1.52

More info and screens

5

3. Growth

3.1 Past

HSCS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -2242.14%.
HSCS shows a strong growth in Revenue. In the last year, the Revenue has grown by 257.69%.
Measured over the past years, HSCS shows a very negative growth in Revenue. The Revenue has been decreasing by -10.10% on average per year.
EPS 1Y (TTM)-2242.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1318.97%
Revenue 1Y (TTM)257.69%
Revenue growth 3Y-10.1%
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

HSCS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 30.07% yearly.
The Revenue is expected to grow by 358.08% on average over the next years. This is a very strong growth
EPS Next Y82.25%
EPS Next 2Y37.04%
EPS Next 3Y30.07%
EPS Next 5YN/A
Revenue Next Year-15.68%
Revenue Next 2Y495.09%
Revenue Next 3Y358.08%
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for HSCS. In the last year negative earnings were reported.
Also next year HSCS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

HSCS's earnings are expected to grow with 30.07% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y37.04%
EPS Next 3Y30.07%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for HSCS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HEARTSCIENCES INC

NASDAQ:HSCS (1/15/2025, 9:45:57 AM)

3.3378

+0.08 (+2.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)12-12 2024-12-12/amc
Earnings (Next)N/A N/A
Inst Owners1.12%
Inst Owner Change0%
Ins Owners5.33%
Ins Owner Change0%
Market Cap3.27M
Analysts82.5
Price Target13.77 (312.55%)
Short Float %3.55%
Short Ratio0.77
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)29.17%
EPS NY rev (1m)0%
EPS NY rev (3m)-4.55%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-9.09%
Revenue NY rev (1m)-96.97%
Revenue NY rev (3m)-96.97%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 175.86
P/FCF N/A
P/OCF N/A
P/B 0.81
P/tB 1.35
EV/EBITDA N/A
EPS(TTM)-50.81
EYN/A
EPS(NY)-6.2
Fwd EYN/A
FCF(TTM)-8.17
FCFYN/A
OCF(TTM)-8.04
OCFYN/A
SpS0.02
BVpS4.1
TBVpS2.47
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -84.93%
ROE -164.44%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 67.31%
FCFM N/A
ROA(3y)-164.63%
ROA(5y)-163.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.97%
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 338.25%
Cap/Sales 672.31%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.72
Quick Ratio 1.52
Altman-Z -14.67
F-Score3
WACC8.76%
ROIC/WACCN/A
Cap/Depr(3y)174.78%
Cap/Depr(5y)108.86%
Cap/Sales(3y)346.2%
Cap/Sales(5y)211.82%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-2242.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1318.97%
EPS Next Y82.25%
EPS Next 2Y37.04%
EPS Next 3Y30.07%
EPS Next 5YN/A
Revenue 1Y (TTM)257.69%
Revenue growth 3Y-10.1%
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-15.68%
Revenue Next 2Y495.09%
Revenue Next 3Y358.08%
Revenue Next 5YN/A
EBIT growth 1Y-3.15%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-28.04%
EBIT Next 3Y2.01%
EBIT Next 5YN/A
FCF growth 1Y-58.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-56.02%
OCF growth 3YN/A
OCF growth 5YN/A